Shield Therapeutics PLC
LSE:STX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Shield Therapeutics PLC
LSE:STX
|
UK |
|
Nipro Corp
F:5FA
|
JP |
|
A
|
Achieve Life Sciences Inc
F:SP4P
|
US |
|
S
|
Sumitomo Metal Mining Co Ltd
OTC:STMNF
|
JP |
|
E
|
Endeavour Group Ltd
OTC:EDVGF
|
AU |
|
K
|
Kopin Corp
F:KOC
|
US |
|
Ecolab Inc
NYSE:ECL
|
US |
Intrinsic Value
Is STX undervalued or overvalued?
See the intrinsic value estimate for Shield Therapeutics PLC and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
STX looks undervalued.
But is it cheap by its own standards?
See how today’s valuation compares with STX’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Shield Therapeutics Does
Shield Therapeutics is a specialty pharmaceutical company focused on treating iron deficiency and iron deficiency anaemia. Its main product is an oral iron medicine designed for patients who cannot tolerate standard iron pills or who need a different way to replace iron. The company sells prescription medicine to healthcare providers and pharmacies, so the real customers are doctors, hospitals, and patients using the treatment under medical supervision.
- Headquarters
- United Kingdom UK
- Employees
- 63
- IPO date
- Feb 26, 2016
Earnings Waterfall
Shield Therapeutics PLC
The intrinsic value for Shield Therapeutics PLC (STX) under the Base Case is hidden GBX.
Compared with the current market price of 5.5095 GBX, the stock appears hidden.